The subsidiary of CSPC Pharmaceutical Innovation (300765.SZ) received a milestone payment of US$15 million in an exclusive licensing agreement with Corbus

Zhitongcaijing · 2d ago

According to Zhitong Finance App, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Biotech”), received a milestone payment of 15 million US dollars from Corbus Pharmaceuticals, Inc. (“Corbus”) on November 18, 2026. Previously, Jushi Biotech has received a total of 17.5 million US dollars in down payments and milestone payments from Corbus under the exclusive licensing agreement (not including this payment). The collection is expected to have a positive impact on the company's performance and financial position.